Form 4: Athira Pharma Director Michael A. Panzara Acquires Stock Options

Director Michael A. Panzara acquired stock options in Athira Pharma, Inc. on May 24, 2024.

Summary

• Michael A. Panzara, a director of Athira Pharma, Inc., acquired 20,900 stock options on May 24, 2024.
• The exercise price of these options is $2.64.
• The options vest on the earlier of May 24, 2025, or the day before the next annual meeting of the Issuer's stockholders after May 24, 2024.
• The options expire on May 23, 2034.
• Following the transaction, Panzara directly owns 20,900 derivative securities.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it is a standard disclosure of stock option acquisition by a director. It doesn't inherently indicate positive or negative performance.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders (directors, officers, or those holding more than 10% of a company's shares) trade in their company's stock. These filings provide transparency to the market.

Stakeholder Impact

• Shareholders may view the acquisition of stock options by a director as a sign of confidence in the company's future prospects.

Key Dates